Calcium channel blockers not found to increase risk of breast cancer
the ONA take:
According to findings presented at the 2014 American Heart Association Scientific in Chicago, Illinois, researchers from the Intermountain Medical Center Heart Institute in Murray, Utah, have found that women who take calcium channel blockers to treat their hypertension are not at increased risk for developing breast cancer.
Prompted by a study conducted last year at the Fred Hutchinson Cancer Research Center in Seattle, Washington, researchers conducted two studies by analyzing data from the records of more than 3,700 women ages 50 to 70 years with no history of breast cancer who had used calcium channel blockers long-term to treat their high blood pressure.
For each study, researchers compared women who had long-term use of calcium channel blockers to similar women who did not take those medications. In one study, they found a slight increase in breast cancer risk, and a 50% decreased risk in the second study.
The second study's findings were significant, but the odds of breast cancer were much lower than those observed in the study at Fred Hutchinson. As a result, the researchers recommend the continued use of calcium channel blockers to treat hypertension, thereby reducing the risk of myocardial infarction and stroke.
Women who take calcium channel blockers to treat their hypertension are not at increased risk.
Researchers analyzed the records of more than 3,700 women who had no history of breast cancer, and who had long-term use of calcium channel blocker medications to control their blood pressure. Researchers found only a minimal increase in risk in one study and a 50 percent reduced risk in a second, leading them to recommend the continued use of these important medications to help prevent heart attack and stroke.
Findings from the Intermountain Medical Center Heart Institute study will be presented at the 2014 American Heart Association Scientific in Chicago at 10:30, EST, on Wednesday, November 19.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- MRD Negativity Associated With Prolonged Survival in Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Patient Navigation Reduces Delays in Diagnostic Resolution
- Fee-for-service Medicare Plans Linked to Improved Care During Last Year of Life
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|